<DOC>
	<DOCNO>NCT01005901</DOCNO>
	<brief_summary>A study ass safety , tolerability efficacy NVA237 versus placebo patient moderate-to-severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Efficacy NVA237 Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>1 . Diagnosis COPD ( moderatetosevere classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines , 2008 ) : Smoking history least 10 packyears Postbronchodilator FEV1 &lt; 80 % â‰¥ 30 % predict normal value Postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % 1 . Patients low respiratory tract infection within 6 week prior Visit 1 2 . Patients concomitant pulmonary disease 3 . Patients history asthma 4 . Any patient lung cancer history lung cancer 5 . Patients history certain cardiovascular comorbid condition 6 . Patients known history diagnosis alpha1 antitrypsin deficiency 7 . Patients active phase supervise pulmonary rehabilitation program 8 . Patients contraindicate tiotropium ipratropium treatment show untoward reaction inhale anticholinergic agent Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>NVA</keyword>
	<keyword>FEV1</keyword>
</DOC>